<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

A Novel Pancreatic Cancer Early Diagnostic Technology

The incidence of pancreatic cancer has been rising by about 1% per year over the past few decades, and it now accounts for ~3% of all cancers and 7% of cancer mortality in the U.S. Pancreatic cancer is now the third leading cause of cancer-related death, and it is exceptionally lethal in part because it is challenging to detect at an early stage. By the time signs and symptoms appear, the disease has often already reached an advanced stage and metastasized. The 5-year survival rate is dismal at 12%, and no clinically relevant diagnostic test can reliably detect early-stage pancreatic cancer in individuals without symptoms.

Scientists at JSR Life Sciences (JLS), the parent company of Crown Bioscience, have developed a novel and unique in vitro pancreatic cancer early detection technology (iv-PCED) that has great potential for detecting pancreatic cancer in its early stages.

The Value of Early Cancer Detection

This novel iv-PCED can play a significant role in the growing field of early cancer detection, for example, akin to other commercially available cancer diagnostic tests. Since survival greatly improves when cancer is detected early and therapies becoming increasingly expensive, there is strong rationale for payors to reimburse for such technologies and ensure proper use of therapeutics. Furthermore, early cancer detection can provide healthcare providers with valuable insights that can guide optimal care for their patients, who are generally becoming better informed, empowered, and tech savvy and want access to better diagnostic (Dx) testing options. The Dx landscape for early cancer detection is evolving rapidly with improved quality and sensitivity, and presents exciting growth opportunities. Companies active in the field of genetic cancer diagnostic technology can benefit on next generation sequencing (NGS) as a powerful technology to detect genomic alterations.

Increasing Role of NGS in Clinical Cancer Research and Care

For highly complex diseases such as cancer, NGS is positioned to play an increasingly important role in diagnosis, prognosis, and therapeutic testing (Figure 1). Furthermore, interest and opportunity are increasing for liquid biopsies which are blood-based tests that can detect cancer cells or DNA circulating in the blood and can reduce reliance on highly invasive surgical biopsies. Since early detection of cancer is intimately tied to better outcomes and survival, it is no surprise that several NGS-based multigene panels have been developed commercially.

Figure 1: Role of NGS technology in cancer diagnosis, prognosis, and therapeutics using an integrative omics approach. From Satam, H. et al. Next-Generation Sequencing Technology: Current Trends and Advancements. Biology 2023, 12(7), 997. Available at: https://doi.org/10.3390/biology12070997. Used under Creative Commons Attribution 4.0 International License: https://creativecommons.org/licenses/by/4.0/.

Novel in vitro Pancreatic Cancer Early Detection Test (iv-PCED)

This novel technology is based on a newly identified and validated panel of biomarkers that are relevant for the early diagnosis of pancreatic cancer. This novel approach, protected by intellectual property, uses a unique genetic cancer biomarker panel consisting of 23 specific fusion points shown to be relevant, in combination with an integrated and proprietary artificial intelligence (AI) algorithm to analyze the fusion points and provide valuable insights. This biomarker panel and companion AI holds great commercial potential as a Dx tool, such as for an in vitro PCED test (Figure 2).

Figure 2: Potential Use of the iv-PCED.

Based on preliminary analyses, the JLS iv-PCED test is predicted to have high selectivity and specificity and may be used as a Direct-to-Consumer (DtC) Dx test in asymptomatic, high-risk individuals (such as those older than 50) and/or a medical Dx test for younger individuals with a family history of pancreatic cancer. The table below highlights the target product profile of the asset (Table 1).

  Primary Secondary
Product Type In vitro Early Detection Genetic Diagnostic Test In vitro Medical Genetic Diagnostic Test
Biomarker Type Diagnostic biomarker
Predictive biomarker
Prognostic biomarker
Monitoring biomarker
Indication Pancreatic cancer (PCa)  
Unmet Need High; PCa is 3rd leading cause of cancer-related death partly due to lack of early diagnosis testing
Product Use Direct-to-Consumer Genetic in vitro Pancreatic
Cancer Early Diagnostic (IV-PCED) Test
Medical Genetic Diagnostic Test for selection
of best treatment regimens in PCa.
Target Population Asymptomatic population at higher risk of
cancer (>50 years old)
Population with an associated family history
of pancreatic cancer
Genetic Biomarker A set of 25 biomarker fusion points occurring
exclusively in Pancreatic cancer. Detection of one
Intellectual Property Patent filing priority date Sept 8, 2021; WO2023039058
Stage of Development Biomarker discovery
Method of Detection In tumor: WGS short reads; in blood: to be developed (WGS short reads or PCR-Amplicon)
Competition None for pancreatic cancer early detection test

Table 1: Target Product Profile of the iv-PCED.

Potential Out-licensing Opportunity

Crown Bioscience is currently seeking partners to out-license this technology platform and is open to negotiating a variety of possible out-licensing models. For instance, our collaborative licensing model offers to the licensee a creditable note against up-front and milestone payments on expenses incurred with JLS affiliated companies (such as Crown Bioscience and MBL) related to the development of the iv-PCED test.

To learn more about this unique out-licensing opportunity, please contact outlicensing@crownbio.com

Related Posts